secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2026-08-10T20:05:18+00:00
Accession:  0001193125-26-342336
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta Q3 FY26 net loss $19.5M; cash $211.5M; RSV and immunology programs on track
--------------------------------------------------------------------------------

- Revenue $14.4M from MAVYRET royalties, down from $18.3M YoY; net loss $19.5M ($0.67/sh) vs $18.3M ($0.85/sh).
- Cash and marketable securities $211.5M; runway into fiscal 2029; OMERS gets 54.5% of royalties through 2032.
- Dosing started in LOTUS Phase 2b pediatric RSV trial of zelicapavir; topline expected 2027; RESOLVE to initiate in 4Q 2026.
- EDP-978 Phase 1 topline data expected 4Q 2026; EPS-3903 IND filing targeted 2H 2026; MRGPRX2 candidate selection 2H 2026.
- Federal Circuit affirmed invalidity of Pfizer patent; Enanta filed rehearing petition; UPC hearing set for Sept 29, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/0001193125-26-342336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-342336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer